MedPath

Emergency Department, Rapid Assessment for Sexually Transmitted Infection

Completed
Conditions
Infection
Registration Number
NCT02386514
Lead Sponsor
Henry Ford Health System
Brief Summary

To evaluate if a rapid urine Nucleic Acid Amplification Testing (NAAT) is non-inferior to the traditional swab NAAT for gonorrhea and chlamydia when performed in the Emergency Department.

Detailed Description

All patients presenting to the Emergency Department during the study period who are tested for gonorrhea and chlamydia by the traditional swab NAAT will concurrently have their urine tested for gonorrhea and chlamydia using the Cepheid GeneXpert rapid NAAT. The result of both tests will be compared to determine if the rapid assay is non-inferior to the current traditional NAAT. Both the traditional and Cepheid GeneXpert rapid NAAT are FDA and CDC approved for evaluation of gonorrhea and chlamydia. However, the Cepheid GeneXpert rapid NAAT has not been prospectively validated in the Emergency Department setting. We intend for both the provider obtaining the sample and the technician running the rapid assay sample to be blinded to the result of the traditional NAAT. The Cepheid GeneXpert rapid NAAT will not be used in patient care decisions.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1200
Inclusion Criteria
  • Clinical concern for gonorrhea and/or chlamydia infection
  • Concurrent testing for gonorrhea and chlamydia using traditional NAAT assay
Exclusion Criteria
  • age <18 years

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Diagnosis of a chlamydia trachomatis or neisseria gonorrhoeae24 hours

comparative test characteristics to traditional swab in the Emergency Department.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath